Abele Jonathan T, Allred Karen, Clare Tracey, Bédard Eric L R
Department of Radiology and Diagnostic Imaging, University of Alberta, 8440-112 St., 2A2.41 WMC, Edmonton, AB, T6G 2B7, Canada,
Ann Nucl Med. 2014 Jun;28(5):477-83. doi: 10.1007/s12149-014-0821-1. Epub 2014 Feb 21.
The goal of our study was to determine if lymph node activity could be visualized using a hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) scanner with two commonly used colloidal lymphatic radiotracers--99mTc-antimony sulfide colloid (ASC) and 99mTc-filtered sulfur colloid (FSC) in the setting of low-stage non-small cell lung cancer (NSCLC).
Patients undergoing CT-guided percutaneous lung biopsies for clinically suspected early-stage lung cancer were randomized to peri-lesional injection of 37 MBq (0.5 mL) of either ASC or FSC. SPECT/CT of the thorax was performed at either 1, 2, or 3 h post-injection. The images were reviewed to determine if lymph node activity separate from the injection site could be identified.
24 patients were included. Lymph node activity was identified in 50% of patients. A total of 15 lymph nodes with activity were visualized including 5 ipsilateral hilar, 6 ipsilateral mediastinal, and 4 distant locations. No contralateral mediastinal or hilar activity was visualized. There was a tendency to improved visualization with ASC and the longer 3 h wait time. Most patients also demonstrated significant pleural, tracheobronchial, and/or systemic activity.
SPECT/CT imaging can demonstrate lymph node activity separate from the injection site in at least some low-stage NSCLC patients with a perilesional injection of 99mTc nanocolloid tracers. Further investigation into the role of pre-operative lymphoscintigraphy with SPECT/CT in patients with lung cancer is warranted.
我们研究的目的是确定在低分期非小细胞肺癌(NSCLC)患者中,使用配备两种常用胶体淋巴显像剂——99mTc-硫化锑胶体(ASC)和99mTc-过滤硫胶体(FSC)的混合型单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)扫描仪,是否能够显示淋巴结活性。
因临床怀疑早期肺癌而接受CT引导下经皮肺活检的患者,被随机分配在病变周围注射37 MBq(0.5 mL)的ASC或FSC。在注射后1、2或3小时进行胸部SPECT/CT检查。对图像进行评估,以确定是否能够识别出与注射部位不同的淋巴结活性。
纳入24例患者。50%的患者显示有淋巴结活性。共显示15个有活性的淋巴结,包括5个同侧肺门、6个同侧纵隔和4个远处淋巴结。未观察到对侧纵隔或肺门有活性。ASC以及3小时的较长等待时间有改善显像的趋势。大多数患者还显示有明显的胸膜、气管支气管和/或全身活性。
SPECT/CT成像能够在至少部分低分期NSCLC患者中显示出与注射部位不同的淋巴结活性,这些患者在病变周围注射了99mTc纳米胶体显像剂。有必要进一步研究术前SPECT/CT淋巴闪烁显像在肺癌患者中的作用。